AbbVie (ABBV)
(Delayed Data from NYSE)
$164.66 USD
+0.41 (0.25%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $164.97 +0.31 (0.19%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
AbbVie (ABBV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$179.37 | $196.00 | $150.00 | 9.21% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for AbbVie comes to $179.37. The forecasts range from a low of $150.00 to a high of $196.00. The average price target represents an increase of 9.21% from the last closing price of $164.25.
Analyst Price Targets (19)
Broker Rating
AbbVie currently has an average brokerage recommendation (ABR) of 1.89 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 1.88 a month ago based on 20 recommendations.
Of the 22 recommendations deriving the current ABR, 11 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 50% and 9.09% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 10 | 10 | 9 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 9 | 9 | 8 | 8 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.89 | 1.89 | 1.88 | 1.88 | 1.98 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/22/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
3/15/2024 | Argus Research Corp. | Jasper Hellweg | Hold | Hold |
2/26/2024 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
2/23/2024 | Berenberg Bank | Luisa Hector | Not Available | Hold |
2/6/2024 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
2/5/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
1/29/2024 | William Blair | Timothy F Lugo | Hold | Strong Buy |
12/1/2023 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
10/29/2023 | SVB Securities | David Risinger | Hold | Hold |
10/27/2023 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
9/6/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.89 |
ABR (Last week) | 1.89 |
# of Recs in ABR | 22 |
Average Target Price | $179.37 |
LT Growth Rate | 7.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 201 of 252 |
Current Quarter EPS Est: | 2.26 |